Beovu market seen growing on retinal disease demand and aging populations

The Business Research Company says the global Beovu market is expanding as retinal disease rates rise, older populations grow and healthcare spending increases. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through 2035.

Why it matters: - Beovu demand is tied to the rising burden of retinal diseases that can cause vision loss, including wet age-related macular degeneration and diabetic macular edema. - The market outlook suggests stronger use of longer-acting anti-VEGF treatments as healthcare systems try to improve convenience, screening and outpatient care. - More information is available through the report sample request.

What happened: - The Business Research Company released its Beovu Market Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report says the Beovu market grew steadily in the historical period and is expected to keep expanding during the forecast period. - Beovu, or brolucizumab, is a prescription monoclonal antibody used for certain eye diseases, including wet AMD and diabetic macular edema. - The drug works by blocking VEGF-A, a protein that drives abnormal blood vessel growth in the eye. - The report says Beovu helps reduce retinal swelling and can slow vision loss caused by abnormal blood vessels.

The details: - The report cites rising retinal disease prevalence, early adoption of anti-VEGF therapies, more ophthalmology clinics and better retinal diagnostic technology as historical growth drivers. - Future growth is expected to come from an aging global population, higher diabetes rates, demand for durable treatment options, expanded retinal screening and more outpatient eye care. - The report highlights a shift toward longer dosing intervals as one of the market’s key trends. - The report also points to growing use of anti-VEGF therapies and more focus on vision preservation in older adults. - The National Eye Institute estimates 2.7 million Americans currently live with glaucoma, rising to 4.3 million by 2030. - The National Eye Institute also estimates 7.7 million Americans have diabetic retinopathy, increasing to 11.3 million by 2030. - The report says the expanding geriatric population is helping drive demand because adults 65 and older face higher risk of AMD and other vision problems. - The UK had 12.7 million people aged 65 or older in 2022, or 19% of the population, according to the UK Parliament's House of Commons Library. - That number is projected to rise to 22.1 million by 2072, equal to 27% of the population. - Rising healthcare spending is another growth factor because higher budgets can expand access to advanced ophthalmic treatments. - The Office for National Statistics reported a 5.6% nominal increase in total healthcare spending in the UK in 2023, a 0.9% rise over 2022. - North America held the largest share of the Beovu market in 2025 because of strong healthcare infrastructure and high awareness of retinal diseases. - Asia-Pacific is projected to be the fastest-growing region through the forecast period because of rising healthcare investment, more retinal disease and broader access to advanced therapies. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and market hotspot infographics. - The company also says the 2026 report set includes updated graphics, tables, key technology analysis and future trend analysis.

Between the lines: - The market case for Beovu is less about a single drug story and more about a broader shift in eye care toward chronic-disease management, earlier detection and longer-lasting therapies. - Regional growth patterns suggest mature markets will remain important revenue centers, while faster expansion may come from healthcare buildout in Asia-Pacific. - The emphasis on dosing convenience and outpatient treatment points to payer and provider demand for therapies that reduce clinic burden.

What's next: - The forecast period runs through 2035, so market gains will likely track diabetes prevalence, aging demographics and screening capacity over the next decade. - Wider adoption will depend on whether ophthalmology systems continue shifting toward anti-VEGF therapies with longer dosing intervals. - The company is offering the full report and expert contact access for buyers evaluating the market.